Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicentre Randomized, Double-blind, Placebo Controlled, Dose-finding, Phase 2 Study (MARS-17) of GSK3858279 in Adult Participants With Moderate to Severe Pain Due to Knee Osteoarthritis

Next Previous
Trial Profile

A Multicentre Randomized, Double-blind, Placebo Controlled, Dose-finding, Phase 2 Study (MARS-17) of GSK3858279 in Adult Participants With Moderate to Severe Pain Due to Knee Osteoarthritis

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 09 Apr 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs GSK-3858279 (Primary)
  • Indications Osteoarthritis; Pain
  • Focus Therapeutic Use
  • Acronyms MARS-17
  • Sponsors GlaxoSmithKline; GSK

Most Recent Events

  • 04 Apr 2025 Status changed from active, no longer recruiting to discontinued.
  • 04 Dec 2024 Planned End Date changed from 26 Nov 2024 to 2 Dec 2024.
  • 19 Sep 2024 Planned End Date changed from 20 Oct 2025 to 26 Nov 2024.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top